Half Year 2025 Vivoryon Therapeutics NV Earnings Call Transcript
Key Points
- Vivoryon Therapeutics NV (FRA:05Y) has demonstrated statistically significant and clinically meaningful improvements in kidney function with varoglutamstat in Phase II studies.
- The company secured a new US composition of matter patent for varoglutamstat, supporting market exclusivity through 2044, with potential for further extension.
- Vivoryon has shown a synergistic effect when combining varoglutamstat with an SGLT-2 inhibitor in preclinical models, enhancing its therapeutic potential.
- The company has maintained a cash runway into January 2026, providing financial stability for ongoing operations.
- Vivoryon is actively pursuing additional financing and partnership opportunities to fund the Phase IIb study, indicating proactive financial management.
- Research and development expenses decreased significantly, indicating a potential slowdown in clinical development activities.
- The company reported a net loss of EUR5.5 million for the first half of 2025, reflecting ongoing financial challenges.
- Cash and cash equivalents decreased to EUR4.8 million as of June 30, 2025, compared to EUR9.4 million at the end of 2024, indicating a reduction in liquidity.
- Vivoryon has not yet initiated any tranches of the standby equity purchase agreement, which could limit immediate access to additional funds.
- The clinical data for varoglutamstat were generated in subjects with Alzheimer's disease, not preselected for kidney disease, which may limit the robustness of the data for kidney disease applications.
Good day and thank you for standing by. Welcome to Vivoryon Therapeutics 2025 half year results earnings goal. (Operator Instructions) Please be advised that today's conference is being recorded.
I would not allow to hand the conference over to our first speaker today, Yaogebauer. Please go ahead.
Thank you, Nadia. Good afternoon, and thank you for joining us today to discuss the company's first half 2025 results and operational update. This morning, Vivoryon issued a press release reporting its first half 2025 financial results and also share an update on the progress we're making in advancing Vivoryon within the kidney disease space. This press release is posted on the Vivoryon's website at www.vivoryon.co. On the call with me today are Vivoryon's Chief Executive Officer, Frank Weber; Vivoryon's Chief Financial Officer, Anne Doering; and Vivoryon's Chief Business Officer, Michael Schaeffer.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
